RALLYBIO CORPORATION Other Nonoperating Income (Expense)
RALLYBIO CORPORATION (RLYB) reported Other Nonoperating Income (Expense) of $424.00 thousand for the 3-month period ending 2026-06-30, per its S-4/A filed 2026-08-26.
Financial Statements › Income Statement › Other Income
us-gaap:OtherNonoperatingIncomeExpense · last filed 2026-08-26
- RALLYBIO CORPORATION other nonoperating income (expense) for the quarter ending 2026-06-30 was $424.00K, a 259.32% increase year-over-year.
- RALLYBIO CORPORATION other nonoperating income (expense) for the quarter ending 2026-03-31 was $254.00K, a 45.98% increase year-over-year.
- RALLYBIO CORPORATION other nonoperating income (expense) for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- RALLYBIO CORPORATION other nonoperating income (expense) for the quarter ending 2025-09-30 was $22.48M, a 8855.78% increase year-over-year.
- RALLYBIO CORPORATION other nonoperating income (expense) for fiscal 2023 was $262.00K, a 23.39% decline from fiscal 2022.
- RALLYBIO CORPORATION other nonoperating income (expense) for fiscal 2022 was $342.00K, a 256.25% increase from fiscal 2021.
- RALLYBIO CORPORATION other nonoperating income (expense) for fiscal 2021 was $96.00K, a 60.17% decline from fiscal 2020.
- RALLYBIO CORPORATION other nonoperating income (expense) for fiscal 2020 was $241.00K.
| Period end | Other Nonoperating Income (Expense) 3 month | Other Nonoperating Income (Expense) 6 month | Other Nonoperating Income (Expense) 9 month | Other Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $424.00K S-4/A · filed 2026-08-26 | $678.00K S-4/A · filed 2026-08-26 | $678.00K derived: sum of 3 quarters · filed 2026-08-26 | $23.16M derived: sum of 4 quarters · filed 2026-08-26 |
| 2026-03-31 | $254.00K S-4 · filed 2026-07-15 | $254.00K derived: sum of 2 quarters · filed 2026-08-26 | $22.73M derived: sum of 3 quarters · filed 2026-08-26 | $22.85M derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-12-31 | $0.00 derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | $22.48M derived: sum of 2 quarters · filed 2026-08-26 | $22.60M derived: sum of 3 quarters · filed 2026-08-26 | $22.77M S-4/A · filed 2026-08-26 |
| 2025-09-30 | $22.48M 10-Q · filed 2025-11-06 | $22.60M derived: sum of 2 quarters · filed 2026-08-26 | $22.77M 10-Q · filed 2025-11-06 | $22.95M derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-06-30 | $118.00K S-4/A · filed 2026-08-26 | $292.00K S-4/A · filed 2026-08-26 | $475.00K derived: sum of 3 quarters · filed 2026-08-26 | $726.00K derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-03-31 | $174.00K S-4 · filed 2026-07-15 | $357.00K derived: sum of 2 quarters · filed 2026-08-26 | $608.00K derived: sum of 3 quarters · filed 2026-08-26 | $751.00K derived: sum of 4 quarters · filed 2026-08-26 |
| 2024-12-31 | $183.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | $434.00K derived: sum of 2 quarters · filed 2026-08-26 | $577.00K derived: sum of 3 quarters · filed 2026-08-26 | $744.00K S-4/A · filed 2026-08-26 |
| 2024-09-30 | $251.00K 10-Q · filed 2025-11-06 | $394.00K derived: sum of 2 quarters · filed 2025-11-06 | $561.00K 10-Q · filed 2025-11-06 | $596.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $143.00K 10-Q · filed 2025-08-07 | $310.00K 10-Q · filed 2025-08-07 | $345.00K derived: sum of 3 quarters · filed 2025-08-07 | $437.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $167.00K 10-Q · filed 2025-05-08 | $202.00K derived: sum of 2 quarters · filed 2025-05-08 | $294.00K derived: sum of 3 quarters · filed 2025-05-08 | $356.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $35.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $127.00K derived: sum of 2 quarters · filed 2025-03-13 | $189.00K derived: sum of 3 quarters · filed 2025-03-13 | $262.00K 10-K · filed 2025-03-13 |
| 2023-09-30 | $92.00K 10-Q · filed 2024-11-07 | $154.00K derived: sum of 2 quarters · filed 2024-11-07 | $227.00K 10-Q · filed 2024-11-07 | $258.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $62.00K 10-Q · filed 2024-08-08 | $135.00K 10-Q · filed 2024-08-08 | $166.00K derived: sum of 3 quarters · filed 2024-08-08 | $264.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $73.00K 10-Q · filed 2024-05-09 | $104.00K derived: sum of 2 quarters · filed 2024-05-09 | $202.00K derived: sum of 3 quarters · filed 2024-05-09 | $302.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $31.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $129.00K derived: sum of 2 quarters · filed 2024-03-12 | $229.00K derived: sum of 3 quarters · filed 2024-03-12 | $342.00K 10-K · filed 2024-03-12 |
| 2022-09-30 | $98.00K 10-Q · filed 2023-11-09 | $198.00K derived: sum of 2 quarters · filed 2023-11-09 | $311.00K 10-Q · filed 2023-11-09 | $420.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $100.00K 10-Q · filed 2023-08-08 | $213.00K 10-Q · filed 2023-08-08 | $322.00K derived: sum of 3 quarters · filed 2023-08-08 | $427.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $113.00K 10-Q · filed 2023-05-09 | $222.00K derived: sum of 2 quarters · filed 2023-05-09 | $327.00K derived: sum of 3 quarters · filed 2023-05-09 | $185.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $109.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $214.00K derived: sum of 2 quarters · filed 2023-03-06 | $72.00K derived: sum of 3 quarters · filed 2023-03-06 | $96.00K 10-K · filed 2023-03-06 |
| 2021-09-30 | $105.00K 10-Q · filed 2022-11-07 | -$37.00K derived: sum of 2 quarters · filed 2022-11-07 | -$13.00K 10-Q · filed 2022-11-07 | $55.00K derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | -$142.00K 10-Q · filed 2022-08-08 | -$118.00K 10-Q · filed 2022-08-08 | -$50.00K derived: sum of 3 quarters · filed 2022-08-08 | $2.00K derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $24.00K 10-Q · filed 2022-05-10 | $92.00K derived: sum of 2 quarters · filed 2022-05-10 | $144.00K derived: sum of 3 quarters · filed 2022-05-10 | $213.00K derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $68.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $120.00K derived: sum of 2 quarters · filed 2022-03-15 | $189.00K derived: sum of 3 quarters · filed 2022-03-15 | $241.00K 10-K · filed 2022-03-15 |
| 2020-09-30 | $52.00K 10-Q · filed 2021-11-10 | $121.00K derived: sum of 2 quarters · filed 2021-11-10 | $173.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $69.00K 10-Q · filed 2021-09-09 | $121.00K 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |